E. Ohman J or Asset Management AB Sells 2,108 Shares of DexCom, Inc. (NASDAQ:DXCM)

E. Ohman J or Asset Management AB lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 15,492 shares of the medical device company’s stock after selling 2,108 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $1,058,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Forvis Mazars Wealth Advisors LLC increased its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. increased its position in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after purchasing an additional 135 shares during the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Nia Impact Advisors LLC increased its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company’s stock valued at $766,000 after purchasing an additional 140 shares during the last quarter. Finally, Level Four Advisory Services LLC increased its position in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock valued at $1,026,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock opened at $86.67 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $118.80. The stock has a market capitalization of $33.98 billion, a price-to-earnings ratio of 60.61, a P/E/G ratio of 2.30 and a beta of 1.46. The stock has a fifty day simple moving average of $76.38 and a two-hundred day simple moving average of $79.04. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. DexCom’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 target price on the stock. Canaccord Genuity Group boosted their target price on DexCom from $103.00 to $106.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Citigroup restated a “buy” rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $98.32.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Sadie Stern sold 6,184 shares of the company’s stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now owns 109,621 shares of the company’s stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 83,110 shares of company stock worth $6,103,505 in the last three months. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.